| 1.25 0.286 (29.63%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.55 |
1-year : | 1.81 |
| Resists | First : | 1.33 |
Second : | 1.55 |
| Pivot price | 1.09 |
|||
| Supports | First : | 1.08 |
Second : | 0.93 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 1.12 |
| MA(100) : | 1.19 |
MA(250) : | 1.16  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.2 |
D(3) : | 20.2 |
| RSI | RSI(14): 60.5 |
|||
| 52-week | High : | 1.86 | Low : | 0.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MXCT ] has closed below upper band by 1.3%. Bollinger Bands are 11.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.35 |
| Low: | 1.07 - 1.08 | 1.08 - 1.08 |
| Close: | 1.23 - 1.25 | 1.25 - 1.27 |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Wed, 14 Oct 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Wed, 14 Oct 2026
MaxCyte MXCT Hires Danaher Dealmaker To Drive Growth - StocksToTrade
Wed, 14 Oct 2026
MaxCyte reports Q3 preliminary revenue $9.1M and raises 2026 revenue guidance to ~$34M - TradingView
Wed, 23 Sep 2026
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer - The Manila Times
Wed, 23 Sep 2026
MaxCyte's new executive has held strategy, innovation and M&A roles over nearly 25 years. - Stock Titan
Fri, 04 Sep 2026
MXCT stock holds steady as MaxCyte prepares next growth steps - AD HOC NEWS
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 61.7 (%) |
| Shares Short | 1,090 (K) |
| Shares Short P.Month | 1,300 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | -114.8 % |
| Operating Margin | -140.8 % |
| Return on Assets (ttm) | -10.7 % |
| Return on Equity (ttm) | -20.4 % |
| Qtrly Rev. Growth | -14.5 % |
| Gross Profit (p.s.) | 0.23 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -3.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.83 |
| Price to Sales | 4.15 |
| Price to Cash Flow | -5.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|